| Autor: |
Rendina D; Department of Clinical Medicine and Surgery, Federico II University, 80131 Naples, Italy., D Elia L; Department of Clinical Medicine and Surgery, Federico II University, 80131 Naples, Italy., Abate V; Department of Clinical Medicine and Surgery, Federico II University, 80131 Naples, Italy., Rebellato A; Department of Medicine, Clinica Medica 3, University of Padova, 35122 Padova, Italy., Buondonno I; Department of Medical Science, Geriatric and Bone Diseases Unit, University of Turin, 10124 Torino, Italy., Succoio M; Department of Molecular Medicine and Medical Biotechnology, Federico II University, 80131 Naples, Italy., Martinelli F; Department of Molecular Medicine and Medical Biotechnology, Federico II University, 80131 Naples, Italy., Muscariello R; Department of Clinical Medicine and Surgery, Federico II University, 80131 Naples, Italy., De Filippo G; Assistance Publique-Hôpitaux de Paris, Hôpital Robert Debré, Service d'Endocrinologie et Diabétologie Pédiatrique, 75015 Paris, France., D Amelio P; Department of Medical Science, Geriatric and Bone Diseases Unit, University of Turin, 10124 Torino, Italy.; Department of Internal Medicine, Service of Geriatric Medicine and Geriatric Rehabilitation, University of Lausanne Hospital Centre, 1011 Lausanne, Switzerland., Fallo F; Department of Medicine, Clinica Medica 3, University of Padova, 35122 Padova, Italy., Strazzullo P; Department of Clinical Medicine and Surgery, Federico II University, 80131 Naples, Italy., Faraonio R; Department of Molecular Medicine and Medical Biotechnology, Federico II University, 80131 Naples, Italy. |
| Abstrakt: |
The vitamin D and microRNA (miR) systems may play a role in the pathogenesis of cardiometabolic disorders, including hypertension. The HYPODD study was a double-blind placebo-controlled trial aiming to assess the effects of cholecalciferol treatment in patients with well-controlled hypertension and hypovitaminosis D (25OHD levels < 50 nmol/L). In addition to this clinical trial, we also evaluated the effects of cholecalciferol and calcitriol treatment on miR-21 expression in vivo and in vitro, respectively. Changes in the cardiovascular risk profiles were evaluated in HYPODD patients treated with cholecalciferol (C-cohort) or with placebo (P-cohort). The miR-21circulating levels were measured in four C-cohort patients and five P-cohort patients. In vitro, the miR-21 levels were measured in HEK-293 cells treated with calcitriol or with ethanol vehicle control. Cholecalciferol treatment increased 25OHD levels and reduced parathormone, total cholesterol, and low-density lipoprotein cholesterol levels in C-cohort patients, whereas no significant changes in these parameters were observed in P-cohort patients. The miR-21 circulating levels did not change in the C- or the P-cohort patients upon treatment. Calcitriol treatment did not affect miR-21 levels in HEK-293 cells. In conclusion, hypovitaminosis D correction ameliorated the cardiovascular risk profiles in hypertensive patients treated with cholecalciferol but did not influence the miR-21 expression. |
